‘It’s Out of Control’: UnitedHealth Group and Peers Charged Americans 1000% More for Drugs

FTC Report Uncovers Massive Markups on Lifesaving Medications

The Federal Trade Commission's latest investigation highlights that the three largest PBMs in the United States—UnitedHealth Group's OptumRx, CVS's Caremark Rx, and Express Scripts—have imposed extraordinary markups on a wide range of prescription drugs. These markups frequently exceed 1,000%, even for generic medications that are typically more affordable alternatives to brand-name drugs.

The report reveals that from 2017 to 2022, these PBMs collectively generated over £5.94 billion ($7.3 billion) in revenue beyond the acquisition costs of the drugs. This practice inflates the cost burden on consumers, particularly for specialty medications used to treat serious conditions such as cancer, HIV, and pulmonary hypertension.

Examples cited include Imatinib, a generic leukemia treatment, and Lamivudine, essential for HIV-positive patients, which was priced at nearly four times its acquisition cost. The FTC's findings suggest that these inflated prices are not isolated incidents but part of a broader trend affecting numerous lifesaving drugs.

Rising Influence of the 'Big 3' Pharmacy Benefit Managers

The FTC's report builds on earlier findings from July 2024, which showed that pharmacies affiliated with the Big 3 PBMs accounted for 68% of dispensing revenue from specialty drugs in 2023, up from 54% in 2016. This growing market dominance allows these companies to exert significant control over drug pricing and distribution.

FTC Chair Lina M. Khan emphasized the seriousness of these developments, noting that the inflated costs impact medications for critical health conditions, including heart disease and cancer. She called for continued investigation and swift action to curb practices that may be illegal or harmful to consumers.

Similarly, Hannah Garden-Monheit, Director of the FTC's Office of Policy Planning, warned that the problem is escalating rapidly, underscoring the urgent need for policymakers to address the issue to protect affordable access to essential medications.

Industry Pushback: Companies Defend Pricing and Highlight Savings

In response to the FTC report, UnitedHealth Group and CVS disputed the findings, challenging the methodology and conclusions. UnitedHealth Group highlighted its efforts to reduce patient costs, stating it has helped eligible patients save approximately £1.058 billion ($1.3 billion) with median out-of-pocket payments around £4.07 ($5). The company emphasized its role in lowering specialty medication costs and providing clinical support for complex conditions.

CVS criticized the FTC for focusing narrowly on generic drugs, which represent a small fraction of overall spending on branded specialty medications. The company claimed that out-of-pocket expenses for customers have decreased by 29% since 2016, attributing this to their cost-saving initiatives.

CVS also warned that regulatory actions targeting PBMs could inadvertently raise drug costs for patients, employers, and taxpayers, urging a comprehensive review of all data rather than selective reporting.

UnitedHealth Group’s Position Amidst Financial Growth and Controversy

UnitedHealth Group remains a dominant force in the healthcare sector, reporting £11.7 billion ($14.4 billion) in profits for 2024, including £4.47 billion ($5.5 billion) in the fourth quarter alone. The company has raised its revenue forecasts for 2025, projecting up to £357.92 billion ($455 billion), reflecting its expansive market presence.

Despite this financial strength, UnitedHealth faces challenges, particularly in administering Medicaid benefits where reimbursement rates often fail to cover care costs adequately. Fitch Ratings has noted that such pressures could impact the company’s margins in this segment.

The company also recently faced a tragic event when UnitedHealthcare CEO Brian Thompson was fatally shot in December 2024. This incident has drawn additional media attention to the company during a period marked by both growth and controversy.

Implications for Patients and Policymakers

The FTC’s findings raise critical questions about the transparency and fairness of drug pricing in the U.S. healthcare system. Patients relying on specialty medications for life-threatening conditions may face prohibitive costs due to inflated markups by PBMs.

Policymakers are now under pressure to consider regulatory reforms that could increase oversight of PBMs and promote more competitive pricing. Ensuring affordable access to essential medications is a priority, particularly as drug costs continue to rise and market consolidation intensifies.

At the same time, industry stakeholders caution that overly aggressive regulation could have unintended consequences, potentially disrupting existing cost-saving programs and increasing overall expenses for consumers.

What this means

The Federal Trade Commission’s report sheds light on alarming practices within the U.S. pharmaceutical supply chain, where major pharmacy benefit managers impose steep markups on critical medications. While companies like UnitedHealth Group and CVS defend their efforts to lower patient costs, the evidence of widespread price inflation cannot be ignored. This situation underscores the urgent need for transparent pricing, stronger regulatory oversight, and policies that prioritize patient access to affordable, lifesaving drugs. As the healthcare landscape evolves, striking a balance between industry innovation, financial sustainability, and consumer protection remains a complex but essential goal.